Loading clinical trials...
Loading clinical trials...
Phase I/II Study of Docetaxel and OSI-774 (Erlotinib) in Solid Tumor Patients With an Emphasis on NSCLC Using Molecular Correlates as Potential Markers of Response
Conditions
Interventions
docetaxel
erlotinib hydrochloride
Locations
1
United States
University of California Davis Cancer Center
Sacramento, California, United States
Start Date
July 1, 2002
Primary Completion Date
August 1, 2008
Completion Date
August 1, 2012
Last Updated
December 6, 2018
NCT06066138
NCT07190248
NCT07486219
NCT07336732
NCT06498635
NCT07485114
Lead Sponsor
University of California, Davis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions